Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GH
stocks logo

GH

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
211.24M
+19.19%
-0.515
+7.34%
226.32M
+18.2%
-0.488
+8.47%
244.70M
+21.25%
-0.490
-20.95%
Estimates Revision
The market is revising Upward the revenue expectations for Guardant Health, Inc. (GH) for FY2025, with the revenue forecasts being adjusted by 3.1% over the past three months. During the same period, the stock price has changed by 9.04%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.1%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-7.15%
In Past 3 Month
Stock Price
Go Up
up Image
+9.04%
In Past 3 Month
18 Analyst Rating
up Image0
Wall Street analysts forecast GH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GH is 61.38 USD with a low forecast of 56.00 USD and a high forecast of 70.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 46.460
sliders
Low
56.00
Averages
61.38
High
70.00
up Image0
Current: 46.460
sliders
Low
56.00
Averages
61.38
High
70.00
Mizuho
Anthony Petrone
Buy
Initiates
$55
2025-04-10
Reason
Mizuho
Anthony Petrone
Price Target
$55
2025-04-10
Initiates
Buy
Reason
Mizuho analyst Bradley Bowers initiated coverage of Guardant Health with an Outperform rating and $55 price target. The firm is bullish on Guardant given: Smart Liquid Biopsy as a differentiated platform versus tissue-based competition; near-term access to nearly $20B of Precision Oncology total addressable market; positive survey response for Guardant's Blood-based colorectal cancer test, and; cash flow/profitability expectations with upside from success of aforementioned products. The firm added that its price target is above peers but deserved given near-term inflection points in sales and profitability.
Barclays
Luke Sergott
Buy
Maintains
$60 → $55
2025-04-10
Reason
Barclays
Luke Sergott
Price Target
$60 → $55
2025-04-10
Maintains
Buy
Reason
Barclays lowered the firm's price target on Guardant Health to $55 from $60 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.
Stephens & Co.
Mason Carrico
Buy
Reiterates
$55
2025-03-26
Reason
Stephens & Co.
Mason Carrico
Price Target
$55
2025-03-26
Reiterates
Buy
Reason
Morgan Stanley
Shannon O'Callaghan
Buy
Maintains
$42 → $52
2025-03-06
Reason
Morgan Stanley
Shannon O'Callaghan
Price Target
$42 → $52
2025-03-06
Maintains
Buy
Reason
Piper Sandler
David Westenberg
Buy
Maintains
$34 → $50
2025-02-26
Reason
Piper Sandler
David Westenberg
Price Target
$34 → $50
2025-02-26
Maintains
Buy
Reason
Piper Sandler analyst David Westenberg raised the firm's price target on Guardant Health to $50 from $34 following quarterly results. The firm keeps an Overweight rating on the shares.
Canaccord Genuity
Kyle Mikson
Strong Buy
Maintains
$42 → $60
2025-02-24
Reason
Canaccord Genuity
Kyle Mikson
Price Target
$42 → $60
2025-02-24
Maintains
Strong Buy
Reason
Canaccord analyst Kyle Mikson raised the firm's price target on Guardant Health to $60 from $42 and keeps a Buy rating on the shares. The firm said they remain bullish after a strong finish to 2024 and solid outlook for 2025 with multiplepotential catalysts. They raise their target on higher margins in their discount free cash flow due to average sellng price tailwinds.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Guardant Health Inc (GH.O) is -25.42, compared to its 5-year average forward P/E of -22.51. For a more detailed relative valuation and DCF analysis to assess Guardant Health Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-22.51
Current PE
-25.42
Overvalued PE
-3.80
Undervalued PE
-41.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-22.51
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-5.89
Undervalued EV/EBITDA
-39.13

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
14.14
Current PS
0.00
Overvalued PS
26.24
Undervalued PS
2.04

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

GH News & Events

Events Timeline

(ET)
2025-07-15
11:02:20
Guardant Health announces patient enrollment in Vanguard Study
select
2025-06-27 (ET)
2025-06-27
10:44:35
Supreme Court keeps element of Obamacare preventive care, Reuters reports
select
link
2025-06-03 (ET)
2025-06-03
08:11:37
Guardant granted Breakthrough Device designation for multi-cancer detection test
select
Sign Up For More Events
Sign Up For More Events

News

Preview
6.5
07-18NASDAQ.COM
Analysts Anticipate FMDE Will Reach $38

  • Fidelity Enhanced Mid Cap ETF Analysis: The Fidelity Enhanced Mid Cap ETF (FMDE) has an implied analyst target price of $37.96 per unit, indicating a potential upside of 10.32% from its current trading price of $34.41.

  • Underlying Holdings Performance: Notable underlying holdings such as Guardant Health Inc, National Storage Affiliates Trust, and Q2 Holdings Inc show significant upside potential based on analyst target prices, prompting questions about the validity of these targets amidst market conditions.

Preview
9.0
07-15Newsfilter
First Patient Enrolled in National Cancer Institute's Vanguard Study Evaluating Guardant Health's Shield Multi-Cancer Detection Test

  • Vanguard Study Enrollment: Guardant Health has initiated patient enrollment for the National Cancer Institute's Vanguard Study, which aims to evaluate the effectiveness of its Shield™ multi-cancer detection test in screening for various cancer types among 24,000 participants aged 45-75 who are cancer-free.

  • FDA Breakthrough Device Designation: The Shield MCD test has received Breakthrough Device Designation from the FDA, highlighting its potential to improve early cancer detection through a simple blood test, thereby enhancing treatment options and potentially saving lives.

Preview
7.0
07-12Reuters
US judge rebukes law firm Quinn Emanuel, awards $3 million sanction in Guardant case

  • Legal Fees Awarded: A federal judge in California has ordered Natera to pay nearly $3 million in legal fees to Guardant Health due to misconduct during a lawsuit over false advertising claims related to colorectal cancer blood tests.

  • Sanctions and Misconduct: The judge criticized Natera's attorneys for misleading the court, which led to trial delays and additional sanctions, while Natera continues to contest the jury's previous verdict awarding Guardant over $292 million in damages.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Guardant Health Inc (GH) stock price today?

The current price of GH is 46.46 USD — it has decreased -1.73 % in the last trading day.

arrow icon

What is Guardant Health Inc (GH)'s business?

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

arrow icon

What is the price predicton of GH Stock?

Wall Street analysts forecast GH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GH is 61.38 USD with a low forecast of 56.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Guardant Health Inc (GH)'s revenue for the last quarter?

Guardant Health Inc revenue for the last quarter amounts to 203.47M USD, increased 20.76 % YoY.

arrow icon

What is Guardant Health Inc (GH)'s earnings per share (EPS) for the last quarter?

Guardant Health Inc. EPS for the last quarter amounts to -0.77 USD, decreased -18.09 % YoY.

arrow icon

What changes have occurred in the market's expectations for Guardant Health Inc (GH)'s fundamentals?

The market is revising Upward the revenue expectations for Guardant Health, Inc. (GH) for FY2025, with the revenue forecasts being adjusted by 3.1% over the past three months. During the same period, the stock price has changed by 9.04%.
arrow icon

How many employees does Guardant Health Inc (GH). have?

Guardant Health Inc (GH) has 1999 emplpoyees as of July 19 2025.

arrow icon

What is Guardant Health Inc (GH) market cap?

Today GH has the market capitalization of 5.76B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free